compounded semaglutide crackdown news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Why the FDA is cracking

These actions targeted specific facilities with documented deficienciesnot the entire compounded medication sector

They can also lead to weight loss by reducing the appetite and delaying gastric emptying [1]

Safety is important, so people with a history of thyroid cancer or certain endocrine conditions might not be eligible

If anxiety is a primary concern, evidence-based treatments such as cognitive behavioural therapy (CBT) and, where appropriate, anxiolytic medications remain the gold standard

Nevertheless, ongoing research efforts should be directed toward understanding the mechanism of the unique obesity phenotype of PWS and developing pharmacological therapies